CMPX
Compass Therapeutics Inc

638
Loading...
Loading...
News
all
press releases
Compass Therapeutics (CMPX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Compass Therapeutics (CMPX Research Report) today and set a price target of $10...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
Buy Rating Affirmed: Compass Therapeutics' Promising Pipeline and Prudent Financial Outlook
Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Compass Therapeutics (CMPX Research Report) and keeping the price target...
TipRanks Financial Blog·1y ago
News Placeholder
CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CMPX stock results show that Compass Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. The post...
InvestorPlace·2y ago
News Placeholder
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line...
Globe Newswire·2y ago
News Placeholder
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Globe Newswire·2y ago
News Placeholder
Compass Therapeutics announces publication of CTX-8371 preclinical data
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...
Globe Newswire·2y ago
News Placeholder
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Foresite Capital Management V LLC
Foresite Capital Management V LLC cut its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX Free Report) by 5.8% in the third quarter, according to its most recent Form 13F filing with the...
Ticker Report·2y ago
News Placeholder
We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St·2y ago
News Placeholder
Research Analysts Offer Predictions for Compass Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX Free Report) Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Compass Therapeutics in...
Zolmax·2y ago

Latest CMPX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.